Mutation-driven drug development in melanoma.
OBJECTIVE
The identification of mutations in signal transduction pathways that are central in melanoma pathophysiology has provided new therapeutic targets for drug development. The purpose of this review is to define those oncogenes for which there are preclinical data supporting clinical trials and to summarize results from clinical investigations.


RESULTS
CKIT mutations were first reported in 2005 but are present in only a small subpopulation of melanoma patients. The validation of inhibitors developed in gastrointestinal stromal tumors has taken several years, but recent evidence suggests that responses can be seen in CKIT mutant melanoma. First reported in 2002, BRAF is mutated in 50% of all melanomas and subsets of other cancers. The melanoma field is leading the clinical trials evaluating the value of targeting BRAF and MEK in BRAF mutant tumors. Results from the first clinical trial with a potent and selective BRAF inhibitor clearly show the therapeutic promise of this approach.


CONCLUSIONS
Larger clinical trials are needed to fully define the efficacy of BRAF and CKIT-directed therapy in melanoma, but early results suggest that this strategy will transform treatment options. Additional potential targets have been identified, and clinical trials evaluating novel drugs against them are underway.
Flaherty
Keith T
KT
Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA. ktflaherty@partners.org
Hodi
F Stephen
FS
Bastian
Boris C
BC
D000818:Animals; D015195:Drug Design; D006801:Humans; D008545:Melanoma / Q000188:drug therapy* / Q000235:genetics*; D009154:Mutation; D015398:Signal Transduction / Q000235:genetics*
Lancet. 2006 Oct 14;368(9544):1329-38
17046465
Br J Cancer. 2006 Sep 4;95(5):581-6
16880785
Melanoma Res. 2009 Jun;19(3):156-66
19434003
J Invest Dermatol. 2006 Jan;126(1):154-60
16417231
Cancer Genet Cytogenet. 1999 Jan 1;108(1):81-3
9973930
Cancer Genet Cytogenet. 2008 Apr 15;182(2):116-21
18406873
Mol Cell Biol. 1985 Mar;5(3):582-5
3887133
Pigment Cell Melanoma Res. 2008 Aug;21(4):492-3
18510589
Clin Cancer Res. 2008 Nov 1;14(21):6821-8
18980976
J Clin Oncol. 1999 Jul;17(7):2105-16
10561265
Nature. 1984 Mar 1-7;308(5954):69-72
6700714
Melanoma Res. 2001 Feb;11(1):75-81
11254118
Clin Cancer Res. 2008 Dec 1;14(23):7726-32
19047099
PLoS One. 2009 May 27;4(5):e5717
19492075
Cancer Cell. 2008 Dec 9;14(6):485-93
19061839
J Clin Oncol. 2006 Sep 10;24(26):4340-6
16908931
Oncogene. 2007 Jul 12;26(32):4738-48
17260012
Nat Genet. 2009 Oct;41(10):1127-32
19718025
J Clin Oncol. 2006 Oct 10;24(29):4764-74
16954519
Clin Cancer Res. 2005 Mar 1;11(5):1983-9
15756024
Nature. 2009 Jan 29;457(7229):599-602
19078957
Oncogene. 2004 Aug 5;23(35):5968-77
15195137
J Natl Cancer Inst. 2003 Dec 17;95(24):1878-90
14679157
Int J Cancer. 2008 Jul 15;123(2):340-347
18398842
J Clin Oncol. 2009 Jun 10;27(17):2823-30
19349552
Cancer. 2006 May 1;106(9):2005-11
16565971
Melanoma Res. 2006 Dec;16(6):471-8
17119447
J Transl Med. 2012 Dec 10;10:246
23228035
Int J Cancer. 2006 Mar 15;118(6):1426-9
16187281
Mol Cancer Ther. 2008 Jun;7(6):1533-42
18566224
Nature. 2002 Jun 27;417(6892):949-54
12068308
Proc Natl Acad Sci U S A. 2007 Dec 26;104(52):20932-7
18093943
Cancer Res. 2003 Jul 15;63(14):3955-7
12873990
Cancer Res. 2003 Sep 15;63(18):5761-6
14522897
Oncogene. 2003 Jun 26;22(26):4092-101
12821943
BMC Cancer. 2006 Apr 01;6:85
16579858
Cancer Res. 2008 Jul 15;68(14):5743-52
18632627
N Engl J Med. 2005 Nov 17;353(20):2135-47
16291983
Br J Cancer. 2005 Apr 25;92(8):1398-405
15846297
J Clin Oncol. 2008 Apr 20;26(12):2046-51
18421059
Cancer Res. 2004 Oct 1;64(19):7099-109
15466206
Cancer Res. 2002 Dec 1;62(23):6997-7000
12460918
J Invest Dermatol. 2005 Dec;125(6):1242-51
16354195
Mol Cancer Ther. 2006 May;5(5):1136-44
16731745